secwatch.observer — SEC 8-K summary
======================================

Issuer:     Verrica Pharmaceuticals Inc. (VRCA)
CIK:        0001660334
Form:       8-K
Filed at:   2025-11-14T23:59:59+00:00
Accession:  0001193125-25-283078
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Verrica Q3 revenue $14.3M (YCANTH $3.6M, license $10.7M); net loss narrows to $0.3M
--------------------------------------------------------------------------------

- Q3 net loss $0.3M ($0.03/sh) vs $22.9M loss ($4.88/sh) in Q3'24; non-GAAP net income $1.2M.
- YCANTH dispensed units 14,093 in Q3 (+4.9% sequentially); nine-month total 37,642 (+120% YoY).
- Received $10M milestone from Torii for Japan YCANTH approval; global Phase 3 for common warts started.
- FDA aligned on Phase 3 design for VP-315 in basal cell carcinoma; positive EMA feedback supports MAA filing.
- Cash $21.1M; sales force expanded to 45 reps, targeting 50 in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1660334/000119312525283078/0001193125-25-283078-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1660334/000119312525283078/d99039d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-283078

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer